A gene therapy from uniQure in early testing, called AMT-180, has the the potential to treat all hemophilia A patients, including those…
Articles by José Lopes, PhD
uniQure is continuing to enroll participants for its global Phase 3 trial (NCT03569891) testing the potential gene therapy AMT-061…
Total joint replacement (TJR) is more common in severe hemophilia patients requiring more frequent treatment, according to a population-based study…
Hemophilia patients may now benefit from financial assistance for out-of-pocket expenses, health insurance premiums, and incidental medical costs following the…
Oxidation of clotting protein factor VIII (FVIII) increased the immune response to the replacement therapy in a mouse model…
Hemophilia patients who develop inhibitors against treatment face markedly higher healthcare costs — about three times those of other…
Preliminary results of a Phase 1/2a trial of the hemophilia AÂ experimental treatment BIVV001 show a significant extension of replacement…
Chronic joint inflammation lowers the health-related quality of life in people with severe hemophilia, a European study reports, and…
Researchers are creating a free web-based calculator that will help physicians determine the best patient-specific preventive regimens for children with…
Many hemophilia B patients experience joint pain, depression and overall poor health, a study reports. Other findings were that women with…